These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17341841)

  • 1. Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
    Matsuya T; Takuma K; Sato K; Asai M; Murakami Y; Miyoshi S; Noda A; Nagai T; Mizoguchi H; Nishimura S; Yamada K
    J Pharmacol Sci; 2007 Mar; 103(3):329-32. PubMed ID: 17341841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
    Carta AR; Pinna A; Tronci E; Morelli M
    Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A; Fenu S; Morelli M
    Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
    Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
    Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
    Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
    Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
    Fenu S; Pinna A; Ongini E; Morelli M
    Eur J Pharmacol; 1997 Feb; 321(2):143-7. PubMed ID: 9063681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
    Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
    Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
    Morelli M; Pinna A
    Neurol Sci; 2001 Feb; 22(1):71-2. PubMed ID: 11487207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
    Rose S; Ramsay Croft N; Jenner P
    Brain Res; 2007 Feb; 1133(1):110-4. PubMed ID: 17196564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
    Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
    Jones CK; Bubser M; Thompson AD; Dickerson JW; Turle-Lorenzo N; Amalric M; Blobaum AL; Bridges TM; Morrison RD; Jadhav S; Engers DW; Italiano K; Bode J; Daniels JS; Lindsley CW; Hopkins CR; Conn PJ; Niswender CM
    J Pharmacol Exp Ther; 2012 Feb; 340(2):404-21. PubMed ID: 22088953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
    Chen JF
    Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.
    Koga K; Kurokawa M; Ochi M; Nakamura J; Kuwana Y
    Eur J Pharmacol; 2000 Nov; 408(3):249-55. PubMed ID: 11090641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
    Chen JF; Fredduzzi S; Bastia E; Yu L; Moratalla R; Ongini E; Schwarzschild MA
    Neurology; 2003 Dec; 61(11 Suppl 6):S74-81. PubMed ID: 14663016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
    Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.